Expression Therapeutics
Manufacturing · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1860 Montreal Rd, Tucker, Georgia, 30084...Phone Number
(678) 278-1140Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Expression Therapeutics
Expression Therapeutics is a clinical-stage biotechnology company focused on developing curative gene therapies for hemophilia A and advanced cell therapies for neuroendocrine tumors (NETs). Utilizing proprietary AI-based technologies, the company operates a state-of-the-art GMP manufacturing facility in Cincinnati, Ohio. Their lead product, ET3, is a next-generation gene therapy aimed at providing long-lasting protection for hemophilia A patients, while their ADEPT-STAR platform targets NETs with innovative cell and gene therapy approaches. The company is dedicated to controlling the entire process from discovery to delivery, ensuring high-quality therapeutic development.Explore more
Expression Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Expression Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Expression Therapeutics launches new products
Check if Expression Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Expression Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Expression Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Expression Therapeutics
Funding: Get notified immidiatlly once Expression Therapeutics has new funding data
Check out if Expression Therapeutics is spiking on competitors!
Earning: See what the market has to say on Expression Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Expression Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Expression Therapeutics
Compare insights from companies similar to Expression Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Expression Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Expression Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Expression Therapeutics.
Expression Therapeutics financials insights
Gather financial insights about Expression Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Debt
$266K
Expression Therapeutics Tech Stack
A closer look at the technologies used by Expression Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
Project
Award, Spending/Investment
Funding
Expression Therapeutics has received an SBA PPP loan in the amount of $266,136 from Wintrust Bank resulting in the retention of 12 jobs.
Funding
Expression Therapeutics News & Media
Expression Therapeutics Appoints Industry Veteran Dr. David Townson as Chief Executive Officer
Seasoned Executive Brings Three Decades of Oncology and Cell Therapy Leadership from Pfizer, Novartis, and Bayer ATLANTA, Dec. 10, 2025 /PRNewswire/ -- Expression Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation cellular therapies, today announced...ArtBlood Signs MOU with Expression Manufacturing for Large-Scale In Vitro Red Blood Cell Production
ATLANTA, April 8, 2025 /PRNewswire/ -- ArtBlood, a biotechnology company specializing in transfusion blood production, announced that it has signed a Memorandum of Understanding (MOU) with Expression Manufacturing LLC ("Expression"), the manufacturing subsidiary of Expression...Expression Therapeutics Announces Promising Phase 1 Results for Groundbreaking Hemophilia A Gene Therapy at ASH
ATLANTA, Dec. 11, 2024 /PRNewswire/ -- Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A at the Annual Meeting of the American Society of Hematology (ASH) in San Diego,...Expression Therapeutics Celebrates Opening of Cell and Gene Therapy Manufacturing Facility in Ohio
CINCINNATI, Dec. 17, 2021 /PRNewswire/ -- Expression Therapeutics, Inc., a fully integrated clinical stage biotechnology company developing novel cell and gene therapies celebrates the opening of its state-of-the-art 43,000 square foot cell and viral vector manufacturing facility in...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Expression Therapeutics
Sign Up For FreeTo access detailed company insights
Expression Therapeutics is a clinical-stage biotechnology company focused on developing curative gene therapies for hemophilia A and advanced cell therapies for neuroendocrine tumors (NETs). Utilizing proprietary AI-based technologies, the company operates a state-of-the-art GMP manufacturing facility in Cincinnati, Ohio. Their lead product, ET3, i... Read More
